Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study on testosterone-induced benign prostatic hyperplasia in rats, hydroxychloroquine significantly reduced prostate-related markers and enhanced therapeutic effects when combined with finasteride, suggesting potential as a new treatment approach.

The researchers in this study identified a new subpopulation of dermal fibroblasts in neonatal murine dermis marked by EGFR, which they report contributes to hair follicle regeneration through the promotion of IGF1, potentially aiding in wound-induced hair follicle neogenesis.

In this report, two cases of non-small cell lung cancer treated with gefitinib showed unexpected hair growth, suggesting a potential new application of EGFR-TKIs for alopecia.

This mini review reports on papulopustular eruptions linked to classical EGFR inhibitors, MEK inhibitors, and amivantamab, highlighting distinct dermatologic toxicities in each treatment context and exploring underlying mechanisms and management strategies.

The researchers reported finding a recessive nonsense variant in the EGFR gene responsible for perinatal lethality in the "Blonde d'Aquitaine" cattle breed, prompting the development of a screening test to help eradicate this genetic flaw.

This case report describes the management of PRIDE complex, a skin and hair condition associated with EGFR inhibitor treatment like cetuximab, emphasizing that it does not require stopping the medication.

This study found that epidermal growth factor receptor inhibitors can induce erosive pustular dermatosis of the scalp, typically appearing sooner and affecting the scalp more extensively compared to other triggers.

This study examined the FDA Adverse Events Reporting System and found new dermatologic adverse events associated with EGFR-TKIs in non-small cell lung cancer patients, such as specific skin, nail, and hair issues, that aren't currently listed on drug labels.

Inhibiting EGFR weakens skin's defense against bacteria.

EGFR-targeted cancer therapy can cause skin issues starting at hair follicles, leading to inflammation.

This study found that in mice, hyper-activated JAK-STAT1 signaling due to EGFR inhibitor treatment leads to scarring alopecia, but JAK1/2 inhibition can restore hair follicle immune privilege and promote new hair growth.

This study demonstrated that disrupting EGFR signaling in mice leads to immune sensitivity compromising the hair follicle's protective environment, but JAK1/2 inhibition can restore this immune privilege and stimulate hair growth, suggesting a potential therapy for scarring hair loss diseases like cicatricial alopecia.

This study reported significant transcriptomic changes in keratinocyte and immune cell populations in a mouse model with EGFR-deficient epidermis, suggesting possible targets for mitigating adverse skin events in EGFR-targeted cancer therapy.

EGFR helps protect hair follicles from bacterial infections.

This case report describes a patient who developed PRIDE syndrome-associated skin issues, including a pruritic papulopustular rash and alopecia, after starting treatment with the EGFR inhibitor erlotinib.

This study developed an Asian human sebocyte cell line from breast skin tissue that can be used for sebaceous gland biology investigations, showing that Y27632 may promote cell growth through EGFR-CRAF-MEK-ERK and AKT pathways.

This study using a genetic mouse model found that S. aureus-driven dysbiosis sustains inflammatory skin side effects from EGFR inhibitors, suggesting prophylactic antibiotic treatment may reduce rash severity without fixing barrier defects.

This study reported that EGFR activation leads to suppression of Stathmin, which may promote synchronized entry into catagen in hair follicles, highlighting potential mechanisms involving EGFR in hair cycle transitions.

In this study, Fumai Paste was found to enhance EGFR expression and accelerate healing in a rat model of vinorelbine-induced skin injury more effectively than magnesium sulfate or saline treatments.

In this study, mouse models with EGFR deficiency showed that disrupted hair follicle cycling leads to increased mast cell numbers and inflammation, suggesting EGFR's role in managing hair cycle transitions and preventing folliculitis.

This article outlines the author's personal strategies for managing dermatological toxicities, such as acneiform rash and dry skin, associated with EGFR inhibitor therapy; it does not present new research findings.

This study observed that the expression of EGF and EGFR increased during goat fetal skin development, suggesting these components play significant roles in skin maturation.

In this study, the researchers found that EGF and EGFR play crucial roles in goat fetal skin development, with their expression increasing progressively during gestation.

This study found that Pmab treatment may alter hair follicle growth cycles, leading to trichomegaly and hypertrichosis, but these effects do not correlate with other skin toxicities.

In this study, aumolertinib improved general health status, functional status, and key symptoms for patients with advanced NSCLC, with an objective response rate of 65.2% and disease control rate of 91.3%, suggesting efficacy and quality of life benefits in first-line treatment.

This study conducted molecular docking and ADME property analysis on 144 newly designed isatin analogs, suggesting they exhibit lead-like properties for targeting EGFR enzymes.

This study found that in South Asian women with PCOS, the severity of non-alcoholic fatty liver disease is strongly linked to early renal dysfunction, as indicated by increased serum creatinine and urinary albumin levels, and reduced eGFR.

This review discusses the presentation and management of skin toxicity from epidermal growth factor inhibitors, highlighting a correlation between cutaneous adverse effects and tumor response, but reports no new clinical results.

This article discusses the cutaneous side effects of erlotinib, an EGFR inhibitor, in a patient with non-small cell lung cancer, reporting nonscarring alopecia and indicative scalp biopsy findings.